ACT-101 is under clinical development by Alpha Cancer Technologies and currently in Phase I for Ulcerative Colitis. According to GlobalData, Phase I drugs for Ulcerative Colitis have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ACT-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ACT-101 overview
ACT-101 is under development for the treatment of myasthenia gravis, multiple sclerosis, colorectal cancer, Crohn's disease, Hashimoto thyroiditis, ulcerative colitis and other IgG-driven diseases. The drug candidate is administered by subcutaneous route. ACT-101 is a genetically engineered recombinant version of a naturally occurring protein known as alpha fetoprotein (AFP) which acts by targeting neonatal Fc receptor (FcRn) and is an immunomodulatory agent. It was also under development for uveitis, rheumatoid arthritis, chronic plaque psoriasis and systemic lupus erythematosus.
Alpha Cancer Technologies overview
Alpha Cancer Technologies (ACT) is a clinical stage biotechnology company that offers development in oncology and auto-immune disease indications. The company products include alpha fetoprotein, immunology platform and targeted chemotherapy platform. It manufACTures products using its proprietary recombinant human alpha fetoprotein with immuno-oncology properties. ACT includes drug master file with FDA manufACTuring, toxicology and human safety. The company provides treatment for myasthenia gravis, multiple sclerosis and autoimmune encephalitis and lupus. It also includes chemotherapy platform for the treatment of solid and liquid tumors. The company collaborates with healthcare universities, cancer and polytherics institutions. ACT is headquartered in Toronto, Ontario, Canada.
For a complete picture of ACT-101’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
